Electrode Pacemaker Permanent Temporary
Intermedics
FDA Clearance Information
The device was cleared through the FDA 510k pathway on May 21, 1987. Manufactured by Intermedics, it is classified as a Class 3 device under product code DTB.
What It Is
FDA-Cleared Indications
- Cardiac pacing when electrical stimulation is needed to treat or prevent an inadequate heart rate.
- Temporary cardiac pacing during cardiac procedures or when short-term rhythm support is required.
- Permanent cardiac pacing for patients with chronic rhythm or conduction disorders requiring long-term pacing.
Clinical Applications
- Temporary pacing during cardiac procedures, including procedures in which transient heart block or bradycardia may occur.
- Temporary pacing after cardiac intervention when short-term support is clinically necessary.
- Permanent pacing for selected patients with symptomatic bradycardia or persistent conduction-system disease.
- Use as part of a compatible pacemaker system to deliver electrical stimulation to the heart.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The electrode must be matched with a compatible pacemaker generator, connector, lead configuration and pacing system.
- Temporary and permanent pacing require different placement, fixation and monitoring strategies; the treating cardiac team determines the appropriate configuration.
- Placement requires imaging and electrical testing to confirm the electrode is positioned correctly and has acceptable sensing and capture thresholds.
- MRI safety cannot be assumed from this historical FDA record. MRI eligibility depends on the complete implanted system and its labeling; older systems may be contraindicated.
- Potential complications include bleeding, infection, vessel or heart-wall injury, lead displacement, failure to capture or sense, arrhythmia and thrombosis.
Frequently Asked Questions
What are the clinical indications for electrode pacemaker permanent temporary?
The device is indicated for managing arrhythmias, particularly during procedures like TAVR, and for patients with chronic bradyarrhythmias.
What outcomes have been reported in clinical studies?
Studies report effective management of arrhythmias and maintenance of heart rate during cardiac procedures, with reduced conduction abnormalities post-TAVR.
What complications have been reported?
Safety data indicate complications such as cardiac tamponade and lead migration, though these are rare occurrences.